Biotech Values

[DewDiligence]

RARE -11%/AH on phase-2 failure:

http://finance.yahoo.com/news/ultragenyx-announces-topline-data-phase-200500842.html

NOVATO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc…today announced topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome (Glut1 DS) patients with seizures. The study did not meet the primary endpoint of reducing the frequency of total number of observable and absence seizures among patients treated from baseline to Week 8 with UX007 compared to placebo. When evaluating each seizure type independently, treatment with UX007 did show a reduction in absence seizures captured on EEG, but not observable seizures captured by diary.